International Diploma in Molecular Biology Applied to Clinical Oncology (second edition)

Background

The main objective of the International Diploma in Molecular Biology Applied to Clinical Oncology is to provide an excellence international educational program with high academic and professional European experts in the different oncological areas for the diagnosis and treatment of cancer-based on molecular biology. Link: www.internationaloncologydiploma.com

Academic Endorsement

The present program has the following endorsements:

➢ University Hospital Center of Liège (Link: http://www.chu.ulg.ac.be/jcms/r_127200/fr/internet-accueil)
➢ Belgian Society of Medical Oncology (Link: www.bsmo.be)
➢ Luxembourg Society of Oncology (Link: https://www.slo.lu/)
➢ Canadian Healthcare Council (Link: http://canadianhealthcarec.ca/)

Program recommended by:

➢ European School of Oncology-ESO (Link: https://www.eso.net/)

Program Duration: 6 months (starting on 13 of April to 13 of October 2019)
Academic Hours: 200 hours
Modality: In class sessions (Quito-Ecuador 13-14 April 2019 and Buenos Aires-Argentina 6-7 July 2019) and on-line
Program Language: English and Spanish
Mobile App: Molecular Oncology

Cost

Inscription: 3,500 USD (includes program access with educational materials, educational platform, mobile App and in class sessions with coffee breaks and buffet lunches).

Program coordination can arrange hotel reservations including breakfast buffet at the hotel conference center with an extra fee of 200 USD per night including taxes (Marriott Hotel in Quito-Ecuador and Hilton Hotel in Buenos Aires Argentina). Program accepts pharmaceutical, public or private organizations sponsorships.
**Note:** hotels and flight tickets are not included in the inscription fee. However, the program can coordinate flight tickets and hotels for an extra cost.

**Inscription payment can be implemented by credit card (online link) or wire transfer.**

**Contact information for inscriptions and payments:**
coordination@internationaloncologydiploma.com

**Payment**

After submitting the inscription form you will receive a confirmation letter with an invoice for the program with payment instructions, by e-mail.

Participants are always responsible for the payment of the tuition fee, even if the employer or an organization will pay the tuition fee. Participants are requested to forward the invoice to their financial department and to make sure the tuition fee is paid before the deadline mentioned in the invoice.

**Cancellation Policy**

If you have registered but are unable to attend, a substitute delegate is welcome at no extra charge. Please, inform the program coordination in advance in writing and be sure that he or she can present identification and a letter from the registered participant.

- Cancellations must be sent in writing to the program coordination
- A cancellation/administration fee of 300 USD will be charged in all cases of cancellation before March 13, 2019
- In case of cancellation after March 13, 2019 no refund will be possible, and the full amount will remain due

**Fellowships**

Each year, the program provides an invaluable opportunity to participate in the program.

Each Fellowship is a stimulating challenge for talented young oncologists or in related areas who seek leading careers in oncology areas in public institutions.

Fellowships cover tuition fee and accommodation in Quito and Buenos Aires. All additional costs – travel expenses, subsistence, etc. – are at the participants’ expense.
Applicants who meet each of the following requirements will be considered for a complete or partial Fellowship:

- You have not attended the program in the past
- You are currently working in public institutions in oncology area
- Limited economic resources to cover the inscription fees

If you are interested in registering for the fellowship program, please make sure you read the Participant Profile to ensure you are eligible for the fellowship.

To submit your fellowship application, you need to send each of the following documents to coordination@internationaloncologydiploma.com:

1. A letter of motivation (max. 400 words!), with a focus on academic excellence and ambitions to pursue a successful oncology areas career. Why should we choose you? Also make sure that you explain why you have a particular interest in molecular oncology area and the reasons for a fellowship application?
2. An extensive curriculum vitae (résumé), including:
   - A list of educational institutes attended + corresponding dates
   - Degree(s) obtained or expected to obtain
   - Work experience + corresponding dates of employment for each position held
   - Research experience + a complete list of publications
3. A copy of diplomas with stamps and/or certification from the institute concerned
4. Two recent letters of recommendation
5. A copy of your passport

Please note that we only accept and assess complete application packages!

Application Deadline: 15 of February 2019. You will be informed about the outcome of the selection procedure by the end of February the latest.

Project Coordination

Europe Coordination: Guy Jerusalem MD., PhD
Latin America Coordination: María del Carmen Cabezas MD., PhD
App-Mobile Application: Molecular Oncology
Europe Coordinator

Guy Jerusalem MD., PhD is head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Afinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer, among others.

Latin America Coordinator

María del Carmen Cabezas MD., PhD, did her specialty studies and PhD at the University of Liège-Belgium (ULg), with a training in Epidemiology at the Erasmus University (Rotterdam-The Netherlands), and Problem Based Learning at Maastricht University, is General Manager of Health & Research Services, main professor in the Faculty of Medicine of the Pontifical Catholic University of Ecuador. At the publication level, she is board member of Science Direct Group and the International Journal of HIV/AIDS Prevention, peer reviewer of several international journals with a high impact factor such as AIDS & Behavior, Peer J, among others. Researcher and Coordinator of clinical studies of phase I-IV, epidemiological, pharma-econmic and public health researchs. She has several publications in international journals as main author and co-author in epidemiology, public health, and pharma-economic topics. Her main interest is the development of international education programs with European and Canadian organizations in support of the education system in Latin America.
Program Modality:

In class sessions, with established academic meetings (Saturday and Sunday) on the dates specified in the program. The training of the participants is complemented by online education tools on the ZOOM visual platform. All participants will have total access to the training through videos, teleconferences and educational materials.

The virtual program will be available on-line (www.internationaloncologydiploma.com) and by mobile app (Molecular Oncology), to assure a complete program access.

Faculty

- Adelin Albert M.Sc., PhD. Professor Emeritus at Liege University (ULg). Professor at the Erasmus Summer Course (ESP) program, Netherlands Institute for Health Sciences (NIHES), University of Rotterdam, Netherlands.
- Guy Berchem MD., PhD. Medical oncologist at the Hospital Center of Luxembourg (CHL), head of the research laboratory Experimental Hemato-Oncology Laboratory (LHCE) at the Public Health Research Center (CRP-Santé) in Luxembourg, president of the National Cancer Institute (INC) and president of the Luxembourg Oncology Society (SLO).
- Vincent Bours MD., PhD. Head of the center for human genetics at the University Hospital Center (CHU) of Liège and professor at University of Liège (ULg).
- Alain Chariot PhD. WELBIO principal investigator in the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA) - signal transduction, medical chemistry laboratory and research director in the National Research Fund (FNRS) of Belgium, GIGA-molecular biology of diseases, laboratory of medical chemistry.
- Pierre Close M.Sc., PhD. Principal Investigator of FNRS, head of the Laboratory of Cancer Signaling at GIGA Institute and professor at ULg.
- Joelle Collignon MD. Researcher and head of clinics at CHU of Liège.
- Jacques De Grève MD., PhD. Head of medical oncology and Head of Laboratory of Molecular Oncology at the Free University of Brussels (ULB), President of the Belgian Society of Medical Oncology (BSMO). President of the Belgian Working party for the Development of National Cancer Guidelines. Professor of medical oncology at ULB.
- Pierre Frères MD. PhD. Medical Oncologist, and Researcher at CHU of Liège.
- Christine Gennigens MD. Head of clinics at CHU of Liège and member of the medical council at CHU of Liège.
- Christine Gilles M.Sc., PhD. Senior research associate at FNRS- Belgium and principal investigator at GIGÀ-cancer.
- Elodie Gonne MD. Medical oncologist and researcher at CHU of Liège.
- Michael Herfs BSc., MSc., PhD. He holds a PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, FNRS of Belgium and ULg.
- Guy Jerusalem MD., PhD. Head of oncology at CHU of Liège, professor at ULg and local principal investigator for the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG).
➢ Agnès Noel MSc., PhD. Director of the research center GIGA- cancer. President of the thematic graduate school in experimental cancerology of FNRS of Belgium. Professor and president of the council of research and valorization in health sciences at ULg.

➢ Elisa Onesti MD. Medical oncologist at CHU of Liège, PhD student at ULg (GIGA research center, laboratory of human genetic).

➢ Stefan Rauh MD. Medical oncologist/ hematologist and president of the cancer platform at Hospital Center Emile Mayrisch, Differdange and Esch (CHEM) Luxembourg, the board of the European Society of Medical Oncology (ESMO), vice president of Luxembourg Society of Oncology (SLO). Professor at the faculty of medicine at the University of Luxembourg.

➢ Brieuc Sautois MD., PhD. Head and professor of Clinics in the department of medical oncology at CHU of Liège, board of the oncology certification- Belgium.

➢ Ingrid Struman M.Sc., PhD. Research associate of the FNRS of Belgium. Laboratory of molecular biology and genetic engineering, ULg.

Short Curriculum Vitae of Program Professors

Adelin Albert M.Sc., PhD

Prominent Belgian professor. He retired as an Emeritus Professor in 2013 but he is still involved in teaching and consultancy activities for universities and hospitals. His research interests include multivariate logistic regression, survival analysis, clinical decision-making, quality control and epidemiology. He acquired a wide experience in the development and application of statistical methods in medicine and biomedical sciences. Author or co-author of over 600 international scientific articles in the field of biostatistics and medical computing.

Guy Berchem MD., PhD

Founder and head of Experimental Cancer Research Laboratory at Health Institute of Luxembourg (LIH). He is president of the Luxemburg Society of Medical Oncology and holds a clinical position leading the oncology platform at Hospital Medical Center of Oncology in Luxembourg. He has more than 70 international scientific publications as author and co-author.
Vincent Bours MD., PhD

Head of the department of human genetics at the University Hospital Center (CHU) of Liège. Professor of genetics at University of Liège (ULg). Patent: Circulating microRNAs for diagnosis of breast cancer. He has more than 220 international publications in high impact factor journals.

Alain Chariot PhD

Renowned Belgian researcher who currently serves as WELBIO principal investigator at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-signal transduction, medical chemistry laboratory and research director in National Fund for Research (FNRS) of Belgium, GIGA-molecular biology of diseases, medical chemistry laboratory. He is the author and co-author of more than 170 international scientific publications, abstracts, and posters.

Pierre Close M.Sc., PhD

Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor of the University of Liège (ULg). He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. He has many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.
Joelle Collignon MD

Head of clinics at University Hospital Center (CHU) of Liège. Researcher in clinical studies phase I-IV. She has high experience in solid and gastrointestinal tumors. She has more than 56 scientific publications as author and co-author.

Jacques De Grève MD., PhD

Head of medical oncology and head of the laboratory of molecular oncology and medical oncology department at the Hospital of Free University of Brussels (ULB). Chairman of the Belgian Society of Medical Oncology (BSMO), editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is professor of medical oncology and coordinator of a course molecular targets in cancer at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has 150 international scientific publications in high impact factor journals.

Pierre Frères MD., PhD

Physician of clinical oncology at University Hospital Center (CHU) of Liège. He has a PhD, the subject of his thesis research is “Role of circulating microRNA in breast cancer” at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA) cancer, human genetics of University of Liège (ULg). He has 21 international publications in oncology as author and co-author.
Christine Gennigens MD

Head of clinics at University Hospital Center (CHU) of Liège, and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. She has more than 30 scientific publications as author and co-author.

Christine Gilles M.Sc., PhD

Outstanding Belgian researcher, she is currently senior research associate at National Research Fund (FNRS) of Belgium and Principal investigator at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-Cancer, which focus on the epithelial to mesenchymal transition in metastatic progression. She has more than 120 international articles, abstracts, and posters as author and co-author.

Elodie Gonne MD

She is currently dedicated to the clinical management of patients with solid tumors and is a researcher in several phases I, II, III / IV studies, at University Hospital Center (CHU) of Liège, Belgium. She has scientific publications as author and co-author.
Michäel Herfs M.Sc., PhD

PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, Belgian National Fund for Scientific Research (FNRS), University of Liège (ULg). He completed his post-doctorate in the laboratory of Professor Christopher Crum at Harvard University (Brigham and Women’s Hospital, Boston). Since 2006, his interest has focused on microenvironment/origin and HPV tumors. He has more than 40 international publications in high impact factor journals.

Guy Jerusalem MD., PhD

Head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer among others.
Agnès Noël M.Sc., PhD

Recognized Belgian researcher. Director of the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-cancer. President of the thematic graduate school in experimental cancerology of the National Fund for Research (FNRS) of Belgium. Professor of molecular cell biology and molecular oncology and president of the council of research and valorization in health sciences at the University of Liege (ULg). Author and co-author of more than 160 international scientific articles.

Elisa Onesti Concetta MD

She currently works as an oncologist at medical oncology department University Hospital Center (CHU) of Liège, Belgium. She is PhD student at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA) Research Center, Human Genetics Laboratory, University of Liège (ULg). She has carried out preclinical research at the "Institute of Cancerology Gustave Roussy", Unit INSERM U981, Villejuif, France. She has more than 40 international scientific publications, abstracts and posters as author and co-author.

Stefan Rauh MD

Medical oncologist/hematologist and president of the cancer platform in Emile Mayrisch Hospital Center, Differdange and Esch (CHEM) in Luxembourg. Chair of the ESMO Practicing Oncologist’s group since 2015 and he was ESMO executive board member (2015-2016). President of the Luxembourg Oncology Society (SLO). Professor at the faculty of medicine of the University of Luxembourg. He has participated in several clinical trials and is a co-author of the European Union Survival Guide for patients with cancer (ECPC) 2017.
Brieuc Sautois MD., PhD

Head and professor of clinics at the department of oncology University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-III. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.

Ingrid Struman M.Sc., PhD

Research associate of the National Fund for Research (FNRS) of Belgium, in the molecular biology and genetic engineering laboratory at University of Liège (ULg). Her components are on angiogenic peptides and the pharmacological treatment of diseases related to thrombosis. She has more than 40 international publications as author and co-author.

Attendance and Participation of Program - Regulations

Participants must complete a minimum of 50% in attendance for in class sessions and 80% in self-learning program, online courses, module exams and tutorial activities to access the final exam. To successfully complete the program, a minimal of 80% must be achieved. Any violation of the stipulated ethic code entails the immediate withdrawal from the program.

General Program

Module 1

Dates: starting on 13 of April to 13 of June 2019
In class sessions: 13 – 14 of April 2019 (JW Marriott hotel Quito - Ecuador)
Quizzes available Module 1: 13 of April 2019 Exam Module 1: 6th of July 2019 – 8 a.m. (Hilton Hotel Buenos Aires-Argentina)
### Module 1 Topics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Professor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer: translational efforts</td>
<td>Jacques De Grève MD., PhD</td>
</tr>
<tr>
<td>Precision medicine and the Belgian Precision initiative</td>
<td>Jacques De Grève MD., PhD</td>
</tr>
<tr>
<td>Hereditary cancers: different management compared to sporadic cancers?</td>
<td>Jacques De Grève MD., PhD</td>
</tr>
<tr>
<td>Workshop: clinical case(s) clinical management of hereditary breast cancer (interactive small group discussion)</td>
<td>Jacques De Grève MD., PhD</td>
</tr>
<tr>
<td>Biology of cancer: viral carcinogenesis part 1 and 2</td>
<td>Michael Herfs BSc., MSc., PhD</td>
</tr>
<tr>
<td>(Lymph)Angiogenesis: mechanism of resistance to drugs</td>
<td>Agnès Noel MSc., PhD</td>
</tr>
<tr>
<td>From seed and soil to pre-metastatic niche</td>
<td>Agnès Noel MSc., PhD</td>
</tr>
<tr>
<td>Cancer and metabolism</td>
<td>Agnès Noel MSc., PhD</td>
</tr>
<tr>
<td>Cancer Associated fibroblasts</td>
<td>Agnès Noel MSc., PhD</td>
</tr>
<tr>
<td>Prostate cancer: management of oligometastatic prostate cancer; intermittent versus continuous androgen deprivation, chemotherapy (docetaxel, cabazitaxel), bone targeting agents, abiraterone, enzalutamide: optimal sequence and side effects of standard treatment options; placing DNA repair into the evolving treatment landscape part 1-2 and 3</td>
<td>Brieuc Sautois MD., PhD</td>
</tr>
<tr>
<td>Metastatic cancer of the uterus (cervical and endometrial cancer)</td>
<td>Christine Gennigens MD</td>
</tr>
<tr>
<td>Cholangiocarcinoma: standard systemic therapy and role of targeted agents.</td>
<td>Joelle Collignonon MD</td>
</tr>
<tr>
<td>Principles of oncogeriatry</td>
<td>Elodie Gonne MD</td>
</tr>
<tr>
<td>Epithelial-to-mesenchymal transitions: potential translation into the clinic. Part 1-2</td>
<td>Christine Gilles M.Sc., PhD</td>
</tr>
<tr>
<td>HER2 positive breast cancer: adjuvant therapy</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>CNS primary tumors</td>
<td>Pierre Frères MD., PhD</td>
</tr>
<tr>
<td>CNS metastases (including leptomeningeal infiltration)</td>
<td>Pierre Frères MD., PhD</td>
</tr>
<tr>
<td>Breast cancer: OE positive HER 2 negative breast cancer, metastatic and adjuvant therapy</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>Workshop: clinical case(s) OE pos HER2 neg breast cancer (interactive small group discussion)</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>Melanoma BRAF V600 Mutations and Melanoma Wild Type</td>
<td>Guy Berchem MD., PhD</td>
</tr>
<tr>
<td>NSCLC: ALK fusion protein – current standards, new approaches, treatment algorithms</td>
<td>Guy Berchem MD., PhD</td>
</tr>
<tr>
<td>Workshop: clinical case(s) melanoma (interactive small group discussion)</td>
<td>Guy Berchem MD., PhD</td>
</tr>
</tbody>
</table>
Module 2

Dates: starting on 14 of June to 14 of August 2019
In class sessions: 6th – 7th of July 2019 (Buenos Aires- Argentina)
Quizzes available Module 2: 14 of June 2019
Exam Module 2: 10 of August 2019, 10:00 am (online)

Module 2 Topics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Professor</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR Mutated NSCLC</td>
<td>Pierre Freres MD., PhD</td>
</tr>
<tr>
<td>Biostatistics. Part 1-3</td>
<td>Adelin Albert MSc., PhD</td>
</tr>
<tr>
<td>Workshop: publication of scientific data</td>
<td>Adelin Albert MSc., PhD</td>
</tr>
<tr>
<td>PI3K pathway</td>
<td>Pierre Close MSc., PhD</td>
</tr>
<tr>
<td>Cancer Stem cells</td>
<td>Pierre Close MSc., PhD</td>
</tr>
<tr>
<td>Minimal residual disease</td>
<td>Pierre Close MSc., PhD</td>
</tr>
<tr>
<td>Systemic mechanism of resistance to therapy</td>
<td>Pierre Close MSc., PhD</td>
</tr>
<tr>
<td>Head and neck</td>
<td>Brieuc Sautois MD., PhD</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>Christine Gennigens MD</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>Joelle Collignon MD</td>
</tr>
<tr>
<td>Targeted therapy in NSCLC</td>
<td>Elisa Onesti MD</td>
</tr>
<tr>
<td>Exosomes</td>
<td>Ingrid Struman MSc., PhD</td>
</tr>
<tr>
<td>Non-coding RNA and cancer</td>
<td>Ingrid Struman MSc., PhD</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Joelle Collignon MD</td>
</tr>
<tr>
<td>Renal Cell Carcinoma (RCC)</td>
<td>Christine Gennigens MD</td>
</tr>
<tr>
<td>Breast cancer: HER2 positive advanced breast cancer</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>Breast cancer: triple negative breast cancer (part 1 - 2)</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>Workshop: clinical case(s) breast cancer HER2 positive or triple negative (interactive small group discussion)</td>
<td>Guy Jerusalem MD., PhD</td>
</tr>
<tr>
<td>Carcinoma of unknown origin</td>
<td>Stefan Rauh MD</td>
</tr>
<tr>
<td>Immunotherapy: Physiopathology and management of common side effects: part 1 and 2</td>
<td>Stefan Rauh MD</td>
</tr>
<tr>
<td>Workshop: clinical cases genito-urinary (interactive small group discussion)</td>
<td>Stefan Rauh MD</td>
</tr>
<tr>
<td>Somatic mutations Part 1-2</td>
<td>Vincent Bours MD., PhD</td>
</tr>
</tbody>
</table>
Module 3

Dates: starting on 15 of August to 15 of October 2019
Quizzes available on the virtual platform: 15 of August 2019

Module 3 Topics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Professor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder cancer</td>
<td>Brieuc Sautois MD., PhD</td>
</tr>
<tr>
<td>Soft Tissue Sarcoma</td>
<td>Christine Gennigens MD</td>
</tr>
<tr>
<td>GIST</td>
<td>Christine Gennigens MD</td>
</tr>
<tr>
<td>Precision Medicine in breast cancer</td>
<td>Elisa Onesti MD</td>
</tr>
<tr>
<td>Cardiotoxicity</td>
<td>Pierre Freres MD., PhD</td>
</tr>
<tr>
<td>Adjuvant Colon cancer</td>
<td>Joelle Collignon MD</td>
</tr>
<tr>
<td>Metastatic colon cancer</td>
<td>Joelle Collignon MD</td>
</tr>
<tr>
<td>New actors in oncogenic signaling pathways</td>
<td>Alain Chariot MSc., PhD</td>
</tr>
<tr>
<td>Precision Medicine</td>
<td>Vincent Bours MD., PhD</td>
</tr>
<tr>
<td>Hereditary Cancers Part 1-2</td>
<td>Vincent Bours MD., PhD</td>
</tr>
</tbody>
</table>

Final Exam

Saturday 19 of October 2019 at 10a.m. (On-line)

Virtual Platform

A personalized e-learning platform will support the access to the contents of each module with their respective evaluations and certifications. In addition, a mobile application tool will provide an interactive webinars access.

Graduation

November 29, 2019 – Colonster Castle (University of Liege), Liege, Belgium (Optional participation).

In case of absence to the graduation ceremony, diploma will be delivered by DHL to the participants.